A First-in-Human Phase 1 Study of Plasmalogen Precursor PPI-1011 in Healthy Adult Volunteers to Assess Safety, Tolerability, and Pharmacokinetics

NCT05969977 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Rhizomelic Chondrodysplasia Punctata

Interventions

DRUG: PPI-1011
DRUG: Placebo

Sponsor

MED-LIFE DISCOVERIES LP

Collaborators

[object Object]